{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:51:36Z","timestamp":1792428696015,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.toxicon.2015.07.333","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T23:18:10Z","timestamp":1438384690000},"page":"141-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"PA","title":["Use of botulinum toxin for genitourinary conditions: What is the evidence?"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-6833","authenticated-orcid":false,"given":"Carlos","family":"Martins da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-8972","authenticated-orcid":false,"given":"Michael B.","family":"Chancellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Patrick","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2015.07.333_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/00365599.2012.752404","article-title":"Treatment of lower urinary tract symptoms: agents for intraprostatic injection","volume":"47","author":"Andersson","year":"2013","journal-title":"Scand. J. Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib2","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00345-012-0984-0","article-title":"An exploratory, placebo-controlled, dose-response study of the efficacy and safety of OnabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity","volume":"31","author":"Apostolidis","year":"2013","journal-title":"World J. Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1212\/WNL.0b013e3182a2ca4d","article-title":"OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity","volume":"81","author":"Chancellor","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.07.333_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100\u00a0U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib5","first-page":"1743","article-title":"Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial","volume":"192","author":"Chuang","year":"2014","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib6","series-title":"European Neuroscience Siciety","author":"Cruz","year":"2011"},{"key":"10.1016\/j.toxicon.2015.07.333_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.toxicon.2015.07.333_bib8","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00192-014-2499-2","article-title":"Trigonal versus extratrigonal botulinum toxin-A: a systematic review and meta-analysis of efficacy and adverse events","volume":"26","author":"Davis","year":"2015","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.toxicon.2015.07.333_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-9056(15)61081-8","article-title":"Real life discontinuation rate of botulinum toxin treatment in 100 patients with NDO","volume":"14","author":"De Ridder","year":"2015","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.toxicon.2015.07.333_bib11","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1569-9056(15)60151-8","article-title":"Durable duration of effect and positive treatment response with long-term onabotulinumtoxinA treatment in patients with over-active bladder syndrome: final results of 3.5 years study","volume":"14","author":"De Ridder","year":"2015","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.toxicon.2015.07.333_bib12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib13","doi-asserted-by":"crossref","first-page":"e1092","DOI":"10.1016\/S1569-9056(15)61080-6","article-title":"Positive response to first onabotulinumtoxinA treatment persists long-term with repeat treatments in patients with neurogenic detrusor overactivity","volume":"14","author":"Denys","year":"2015","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.toxicon.2015.07.333_bib14","first-page":"2416","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib15","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/S1569-9056(15)60150-6","article-title":"Onabotulinumtoxin A improves the symptoms of urgency and incontinence and provides treatment benefit in patients with overactive bladder regardless of incontinence severity at baseline","volume":"14","author":"Drake","year":"2015","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.toxicon.2015.07.333_bib16","first-page":"2131","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"Onabotulinumtoxin a is effective in patients with urinary incontinence due to neurogenic detrusor activity regardless of concomitant anticholinergic use or neurologic etiology","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.toxicon.2015.07.333_bib18","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S1569-9056(14)60683-7","article-title":"Consistent long-term efficacy and safety of OnabotulinumtoxinA in patients with neurogenic detrusor overactivity: final results of repeated treatments up to 4 years","volume":"13","author":"Karsenty","year":"2014","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.toxicon.2015.07.333_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/ijcp.12360","article-title":"Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure","volume":"68","author":"Karsenty","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.toxicon.2015.07.333_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","article-title":"Long-term efficacy and safety of OnabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis","volume":"81","author":"Kennelly","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.toxicon.2015.07.333_bib21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated OnabotulinumtoxinA for patients with overactive bladder: a single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib22","first-page":"1","article-title":"Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder","volume":"18","author":"Malde","year":"2014","journal-title":"B.J.U. Int."},{"key":"10.1016\/j.toxicon.2015.07.333_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","article-title":"A\u00a0randomized double-blind placebo-controlled phase 2 dose-ranging study of OnabotulinumtoxinA in men with benign prostatic hyperplasia","volume":"63","author":"Marberger","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-9056(15)60152-X","article-title":"Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder syndrome","volume":"14","author":"Marcelissen","year":"2015","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.toxicon.2015.07.333_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","article-title":"Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study","volume":"62","author":"Maria","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.toxicon.2015.07.333_bib26","first-page":"150","article-title":"A\u00a0multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200\u00a0U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"192","author":"McVary","year":"2014","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"B.J.U. Int."},{"key":"10.1016\/j.toxicon.2015.07.333_bib28","first-page":"2186","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib29","first-page":"e400","article-title":"Long-term efficacy and safety of repeat onabotulinumtoxina treatment in overactive bladder syndrome and urinary incontinence: third interim analysis, median 2.4 year follow-up","volume":"191","author":"Nitti","year":"2014","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.toxicon.2015.07.333_bib30","doi-asserted-by":"crossref","first-page":"e1091","DOI":"10.1016\/S1569-9056(15)61079-X","article-title":"Relative potency and diffusion capacity of onabotulinumtoxinA and abobotulinumtoxinA after injection in the bladder wall","volume":"14","author":"Oliveira","year":"2015","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.toxicon.2015.07.333_bib31","article-title":"Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity","author":"Peyronnet","year":"2014","journal-title":"Neurourol. Urodyn"},{"key":"10.1016\/j.toxicon.2015.07.333_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bju.12028","article-title":"Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(\u00ae) ) or abobotulinumtoxinA (Dysport(\u00ae) ) make a difference?","volume":"112","author":"Ravindra","year":"2013","journal-title":"B.J.U. Int."},{"key":"10.1016\/j.toxicon.2015.07.333_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-9056(15)60677-7","article-title":"A\u00a0randomised clinical trial comparing prostatic injection of botulinum neurotoxin type A (Botox\u00ae) to optimized medical therapy in the treatment of LUTS related to BPH: the PROTOX study","volume":"14","author":"Robert","year":"2015","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.toxicon.2015.07.333_bib34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.toxicon.2015.07.333_bib35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin A","volume":"342","author":"Schurch","year":"2000","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.toxicon.2015.07.333_bib36","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100\u00a0U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","volume":"68","author":"Sievert","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.toxicon.2015.07.333_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the relax study)","volume":"62","author":"Tincello","year":"2012","journal-title":"Eur. Urol."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004101011530026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004101011530026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T10:00:07Z","timestamp":1537437607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004101011530026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":37,"alternative-id":["S004101011530026X"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2015.07.333","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of botulinum toxin for genitourinary conditions: What is the evidence?","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2015.07.333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}